Fig. 5.
Signature of therapeutic response in TN-09. (a) Analysis of the 1509 probe sets regulated between the CTLA4-Ig responders (n = 8) and rapidly progressing placebo-treated individuals (n = 7) matched for baseline I.I.359 at the 3 month time point. The top three panels (left to right) illustrate two-way clustering of the selected and excluded participants in each arm. Left panel, mean expression of the four groups. Middle panel, participants selected for the analysis. Right panel, remaining CTLA4-Ig- and placebo-treated participants. Lower three panels, expression levels of a selected set of well-annotated transcripts. The colour bar indicates assigned treatment arm: red, placebo; blue, CTLA4-Ig. Note: samples were not available for two placebo-treated participants at the 3 month time point. The annotated dataset is available from the corresponding author on request. (b) Mean expression levels of the 1509 differentially induced probe sets at 12 and 24 months. (c) Upstream regulator analysis using IPA. A z score >2.0 is significantly activated; a z score >−2.0 is significantly inhibited. (d) CTLA4-Ig add-back experiment. The mean induced expression levels of the 1509 probe sets after plasma of five local untreated individuals with diabetes were supplemented with 0 μg/ml, 25 μg/ml or 82 μg/ml CTLA4-Ig are shown. ROT1D, recent-onset type 1 diabetes